Cabergoline

Cabergoline is effective when the diagnosis is correct: confirmed hyperprolactinemia with associated symptoms. In this setting, the response can be dramatic, sexual function, libido, and mood often improve substantially within 1–2 weeks.

Use case: Secondary tool for confirmed prolactin problems, usually in 19-nor cycles.

Administration: Keep dosing conservative because the half-life is long and side effects can linger.

Decision rule: Do not use it just because a compound has a 19-nor reputation. Confirm the problem first.

Stop or seek review if: dizziness, compulsive behavior, or severe mood changes appear.

Prolactin begins falling within days of first dose. Symptomatic improvement typically follows within 1–2 weeks if prolactin was the primary driver. If symptoms do not improve, other causes should be investigated rather than escalating cabergoline dose.

Cabergoline is a dopamine D2 receptor agonist used to reduce elevated prolactin levels. Its primary role in the performance context is managing prolactin-related side effects from 19-nor compounds (Trenbolone, Nandrolone, Trestolone) that have progestogenic activity and can drive prolactin elevation.

Elevated prolactin in men causes lactation from nipple tissue (galactorrhea), sexual dysfunction (anorgasmia, inability to maintain erection), reduced libido, and mood disruption. These symptoms are frequently misattributed to estrogen or other hormonal issues before prolactin is measured.

When to use it: The decision to use cabergoline should be based on measured prolactin, not on compound reputation. Many users on Trenbolone or Nandrolone cycles maintain prolactin within normal range. Running cabergoline prophylactically without confirmed elevation adds dopaminergic drug exposure without clear benefit.

The 7-day half-life means twice-weekly dosing is appropriate. Effects are slow to onset and slow to reverse. A typical initial dose is 0.25mg twice weekly, titrated against symptom response and prolactin labs.

Adding cabergoline preemptively to every 19-nor cycle regardless of measured prolactin. This exposes the user to dopaminergic side effects (nausea, dizziness, hypotension, and in rare cases compulsive behaviors) without clear indication.

Using cabergoline without first checking whether estrogen is the actual driver of nipple-related symptoms. High estrogen is more common than high prolactin as a cause of gynecomastia sensitivity on most cycles. Lab-first approach prevents misdiagnosis.

Running too high a dose for too long. Prolactin below normal range is not harmless; it can cause low mood, motivation problems, and reduced sex drive in its own right.

Compared with reducing the causative compound dose, cabergoline is the secondary intervention. If a user is running 600mg Trenbolone and has severe prolactin elevation, dose reduction addresses the source; cabergoline manages the effect. Using cabergoline to tolerate dose levels that produce physiologic dysfunction is generally an error in priority.